Prosecution Insights
Last updated: November 04, 2026
Application No. 19/064,698

METHOD FOR TREATING LOCAL LESION DISEASE

Non-Final OA §102§103§112
Filed
Feb 27, 2025
Priority
Aug 31, 2018 — CN 201811009698.8 +2 more
Examiner
KETCHAM, KAREN A
Art Unit
1614
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Kuachang Inc.
OA Round
1 (Non-Final)
21%
Grant Probability
At Risk
1-2
OA Rounds
1y 9m
Est. Remaining
61%
With Interview

Examiner Intelligence

Grants only 21% of cases
21%
Career Allowance Rate
12 granted / 57 resolved
-38.9% vs TC avg
Strong +40% interview lift
Without
With
+39.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
45 currently pending
Career history
120
Total Applications
across all art units

Statute-Specific Performance

§101
1.8%
-38.2% vs TC avg
§103
56.7%
+16.7% vs TC avg
§102
12.7%
-27.3% vs TC avg
§112
21.5%
-18.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 57 resolved cases

Office Action

§102 §103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Priority This application is a DIV of 17/272,205 filed 02/26/2021 ABN. Information Disclosure Statement The Information Disclosure Statement (IDS) submitted on 02/27/2025 is in compliance with the provisions of 37 CFR 1.97. Accordingly, this IDS has/have been considered by the Examiner. Claim Objections Claim 1 is objected to because of the following informalities: Claim 1 recites “≥2.5” in line 5 of the claim without a unit of measurement. Applicants may consider amending (e.g., % m/v, grams per mL) to provide clarity. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-4, 8 and dependent claims thereof are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 recites “the amino based nutrient in the pharmaceutical composition is ≥2.5.” While concentration (w/v) is recited in line 4, the 2.5 remains indefinite because there are no units shown for 2.5 number. For example weight (or mass) over volume could be expressed as (kg/m3), (g/L), or (% m/v) calculated as grams of solute per 100 mL of solution. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1, 7 and 10-12 are rejected under 35 U.S.C. 102(a)(1) and/or (a)(2) as being anticipated by Berkson (WO 2006/055726 A2, published 05/26/2006) evidenced by Skin Safe (PCCA emollient cream base, last updated 10/20/2017). Berkson discloses a topical medicinal composition comprising nitroglycerin, arginine and curcumin suspended in an emollient cream and zinc containing ingredient wherein there are 10 parts of nitroglycerin and approximately 10 parts arginine and approximately 1 part curcumin (claims 1-4). Berkson teaches that improved composition for treatment for non-healing and slow-healing wounds and ulcerations that effects and utilizes synergistic action of arginine, nitroglycerin and curcumin (page 10, line 18). Berkson discovered that the nitroglycerin, arginine, and curcumin work synergistically to increase the absorption and distribution of each other, as well as to effect an unprecedented therapeutic result (page 11, line 10). Examples demonstrate lesions that underwent either 2, 3 or 4 days of treatment went from open and infected to being completely closed or improved by 50 percent (page 13, line 3 to page 14 line 4). Berkson teaches PCCA emollient cream as a carrier (page line ). As evidenced by Skin Safe, PCCA emollient cream comprises water (see ingredients list on the document provided). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. § 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. § 103 (a) are summarized as follows: Determining the scope and contents of the prior art. Ascertaining the differences between the prior art and the claims at issue. Resolving the level of ordinary skill in the pertinent art. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-14 are rejected under 35 U.S.C. § 103 as being unpatentable over Himi et al. (US 2015/0359864 A1) evidenced by Kawai et al. (US 2007/0110753 A1) and further in view of Kulcsar (WO 1995/013061). Himi discloses a method for preparing a formulation comprising one or more types of peptides with the use of the same solvent in a simple manner without the need for selecting an adequate solvent for each peptide in accordance with its solubility (abstract). Himi teaches a pharmaceutical composition comprising one or more types of peptides as active ingredients and a basic amino acid and/or a base (claim 1), wherein the basic amino acid is one basic amino acid or a combination of two or more basic amino acids selected from the group consisting of arginine, lysine, ornithine, histidine, hydroxylysine, and a salt of any thereof (claim 2); wherein the base are one base or a combination of two or more bases selected from the group consisting of sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydroxide, potassium hydroxide, triethanolamine, trometamol, and meglumine (claim 3). Himi teaches that a “basic amino acid” is an amino acid having basic properties and specific examples thereof include lysine, arginine, ornithine, and histidine and may be an L-, D-, or racemic amino acid (paragraph [0060]). The preferred basic amino acid is arginine and further L-arginine (paragraph [0060]). Basic amino acid content in the pharmaceutical composition of the present invention is not particularly limited (paragraph [0060]). In the case of injection preparations, Himi discloses that it is 15 mg/mL or more (paragraph [0060]). In the case of a hypodermic injection preparation, for example, the L-arginine concentration in the pharmaceutical composition of the present invention can be up to 20 mg/mL (when 1 mL of the pharmaceutical composition of the present invention is to be administered) (paragraph [0060]). The Examiner notes that one skilled in the art would know that a hypodermic injection can be used for local administration. Here Himi reads on the concentration of arginine in instant claims 4-6 with the disclosure of 15 mg/mL to meet the claim limitations. Himi also teaches that when a basic amino acid is L-arginine, accordingly, the L-arginine concentration in the aqueous solution can be 40 mg/mL or less (paragraph [0077]). Himi teaches that the pharmaceutical composition of the present invention can comprise a base instead of or in combination with a basic amino acid (paragraph [0061]). Specific examples include sodium hydroxide, sodium carbonate, sodium bicarbonate, triethanolamine, trometamol, and meglumine (paragraph [0061]). Examples of bases that can be preferably used for the pharmaceutical composition of the present invention include sodium carbonate and sodium bicarbonate (paragraph [0061]). Sodium carbonate and sodium bicarbonate may be in the form of hydrates (paragraph [0061]). According to a preferable embodiment, a base is sodium carbonate or a hydrate thereof (e.g., Na2CO3 · 10H2O) (paragraph [0061]). Base content in the pharmaceutical composition of the present invention is not particularly limited. In the case of an injection preparation, it is 0.5 mg/ml or more, 1 mg/ml or more, 2 mg/ml or more, further preferably 3 mg/ml or more, and most preferably 5 mg/ml or more (paragraph [0061]). In the case of a hypodermic injection preparation, for example, the maximal amount of sodium carbonate decahydrate (i.e., Na2CO3 · 10H2O) used per day is 20.8 mg (i.e., 7.7 mg of sodium carbonate (Na2CO3)) (paragraph [0061]). When the pharmaceutical composition of the present invention is a hypodermic injection preparation comprising sodium carbonate as a base, accordingly, the sodium carbonate decahydrate concentration can be 20.8 mg in the pharmaceutical composition of the present invention; that is, the sodium carbonate concentration can be up to 7.7 mg/mL (when 1 mL of the pharmaceutical composition of the present invention is to be administered) (paragraph [0061]). Here Himi reads on the concentration of sodium carbonate in instant claims 4-6. Himi provides a teaching of a composition of 40 mg/ml of arginine (paragraph [0077]), sodium carbonate (paragraph [0061]), and saline (e.g., paragraph [0067]) for administration to treat gastric cancer ([0033]). Himi teaches gastric cancer (paragraph [0072]). As evidenced by Kawai et al., gastric cancer is a solid (tumor) cancer (paragraph [0013], claim 21). Himi differs from the claimed invention only in that there is no teaching of synergy. However, Kulcsar discloses a pharmaceutical compositions for prevention and treatment of cancerous diseases and a process for their preparation (abstract). The compositions comprise at least three compounds occurring in the circulatory system; at least one amino acid, at least one vitamin and at least one member selected from the group consisting of adenine, 2-deoxy-l)-ribose, D-mannose, D-glucosamine, malic acid, oxalacetic acid and adenosine triphosphate (abstract, claim 1). Kulcsar discloses that using together at least three from the following endogenous and exogenous natural substances occurring in the circulatory system, namely amino acids, vitamins, nucleic bases, carbohydrates and cell-metabolic products synergistically increase the effect of each other and thus are able to destroy tumor cells (page 2, lines 32-37). The qualitative and quantitative composition of the most effective mixture can be determined using the synergism as a criteria (page 3, line 12). Figure 1 shows the effects and synergistic co-operation of components of compositions comprising four and five active components (page 6, lines 24-25). Kulcsar teaches that the amino acid may be L-arginine (claim 3) and is present from 1.1-48% by mass of the composition (claim 7). Example 23 has 33% by mass sodium hydrogen carbonate (i.e., sodium bicarbonate) and 44% by mass L-arginine with an increased effect compared with L-arginine alone (page 14, lines 13-15; page 16, see Table 2). While It would have been prima facie obvious to combine the teachings of Himi and Kulcsar and reasonably expect success. One skilled in the art would be motivated to do so because Kulcsar provides and shows results from experiments that teach and suggest arginine with a synergist (e.g., cell-metabolic products, sodium hydrogen carbonate) provide a synergistic effect in treating cancer cells and tumors. Kulcsar discloses compositions that show an enhancement of selectivity and are soluble in water and thus are easy to dose (page 22, lines 20 and 35). This complements the compositions of Himi where it was discovered that an aqueous solution containing sodium carbonate and/or arginine can dissolve various types of peptides and has a pH level within an adequate range for an injection formulation (paragraph [0013]). Regarding claim 7, Himi teaches that the pharmaceutical composition is used for inducing an immune response to a tumor (claim 8). Regarding claim 8, “results in inhibition of the tumor growth” is a reciting of intended use and must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from what is in the prior art. If the structure described in the prior art is capable of performing such an intended use as claimed, then it meets the requirements of the instant claim. Further, where applicant claims a composition in terms of a function, property or characteristic and the composition of the prior art is the same as that of the claim but the function is not explicitly disclosed by the reference, the examiner may make a rejection under both 35 U.S.C. 102 and 103. Regarding claim 9, Himi teaches sterilization for injection formulations (paragraph [0002]) and that the pharmaceutical composition of the present invention can be in the form of powders (paragraph [0064]). Here Himi’s teachings render the sterile dry powder limitation obvious. Regarding claims 10-12, as mentioned above Himi teaches saline solution. Regarding claim 13, as mentioned above, Himi with evidence from Kawai, gastric cancer taught is a solid cancer. Regarding claim 14, Himi teaches the Himi teaches that examples of tumors or cancers to which the pharmaceutical composition of the invention is applicable include, but are not limited to, bladder cancer, breast cancer, uterine cervical cancer, uterine body cancer, bile duct cancer, colon cancer, esophageal cancer, gastric cancer, hepatic cancer, lung cancer, osteosarcoma, synovial sarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, soft tissue tumor, testicular tumor, mesothelial tumor, head and neck cancer, skin cancer, lymphoma, chronic myelocytic leukemia, and acute myelocytic leukemia (paragraph [0072]). For the foregoing reasons the instant claims are rendered obvious by the teachings of the prior art. Conclusion Claims 1-14 are rejected. No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen A. Ketcham whose telephone number is (571)270-5896. The examiner can normally be reached M-F, 9-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Ali Soroush can be reached at 571-272-9925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Karen A Ketcham/Examiner, Art Unit 1614 /ALI SOROUSH/Supervisory Patent Examiner, Art Unit 1614
Read full office action

Prosecution Timeline

Feb 27, 2025
Application Filed
Oct 26, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12593838
STABLE AGROCHEMICAL COMPOSITION
3y 6m to grant Granted Apr 07, 2026
Patent 12533302
SYSTEMS AND METHODS FOR DELIVERY OF ACTIVES & HEALING TISSUE
3y 11m to grant Granted Jan 27, 2026
Patent 12508233
GRAFT COPOLYMERS, METHODS OF FORMING GRAFT COPOLYMERS, AND METHODS OF USE THEREOF
4y 8m to grant Granted Dec 30, 2025
Patent 12178800
SULFORAPHANE-MELATONIN-LIKE COMPOUND
3y 10m to grant Granted Dec 31, 2024
Patent 12097180
SWINE MATERNAL NEONATAL PHEROMONE
4y 0m to grant Granted Sep 24, 2024
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
21%
Grant Probability
61%
With Interview (+39.9%)
3y 6m (~1y 9m remaining)
Median Time to Grant
Low
PTA Risk
Based on 57 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month